# GOAL.MD > Veteran-owned, physician-led telehealth platform offering physician-supervised treatments for weight loss, anti-aging, sexual health, strength, and wellness — including FDA-approved brand-name medications (Ozempic®, Wegovy®, Zepbound®) and compounded formulations prepared by licensed U.S. 503A/503B pharmacies — with no auto-billing and no subscriptions. GOAL.MD connects patients with licensed physicians who prescribe personalized treatment plans, with medications delivered directly to their door. We are BBB A+ accredited, LegitScript certified, HIPAA compliant, and licensed in all 50 US states. Unlike other telehealth companies, GOAL.MD never auto-bills — we contact you before every renewal. Phone: 314-907-3103 / 800-674-2855. Email: customer@jellyfish.md. ## Pages - [Home](/): Physician-led telehealth for weight loss, longevity, and wellness. - [About](/about): Our veteran-owned, physician-led story and values. - [Contact](/contact): Phone, email, and support hours. - [How It Works](/#how-it-works): The assessment, physician match, and delivery process. ## Weight Loss - [Weight Loss Overview](/weight-loss): GLP-1 and metabolic weight loss programs. - [GLP-1 Program](/weight-loss/glp-1): Core physician-led GLP-1 weight loss program. - [Semaglutide Injection](/weight-loss/semaglutide-injection): Compounded semaglutide, all-inclusive care. - [Semaglutide Micro-Dose](/weight-loss/semaglutide-microdose): Low-dose semaglutide for better tolerability. - [Tirzepatide Injection](/weight-loss/tirzepatide-injection): Dual-action GIP/GLP-1 weight loss. - [Synergy Program](/weight-loss/synergy): Combination metabolic weight loss support. - [Bella Capsules](/weight-loss/bella-capsules): Oral weight loss support. - [Brand-Name GLP-1 Access](/weight-loss/brand-access): Physician + coaching for Ozempic, Wegovy, and Zepbound. - [Ozempic](/weight-loss/ozempic): Brand-name semaglutide access. - [Wegovy](/weight-loss/wegovy): Brand-name semaglutide access. - [Zepbound](/weight-loss/zepbound): Brand-name tirzepatide access. ## Other Treatments - [Anti-Aging & Longevity](/anti-aging): NAD+, rapamycin, peptides, and skin therapies. - [Strength & Recovery](/strength): Sermorelin, NAD+, and B12 therapies. - [Mood & Energy](/mood): NAD+, methylene blue, and vitamin therapies. ## Peptide Education Library (Educational Only, No Ordering) - [Peptide Education Library](/peptides): How peptide ingredients are categorized by regulatory status, and what a physician consultation covers. - [Peptide Ingredients Index](/peptides/ingredients): Educational ingredient index with regulatory status on every entry. - [Tesamorelin](/peptides/tesamorelin): Tesamorelin is FDA-approved only for abdominal fat reduction in HIV-associated lipodystrophy. Learn what that approval covers, and what it does not. - [Ipamorelin](/peptides/ipamorelin): Ipamorelin is not FDA-approved. Its compounding availability has been shaped by FDA 503A/503B bulk substance decisions that require ongoing verification. - [CJC-1295](/peptides/cjc-1295): CJC-1295 is investigational, not FDA-approved. Learn the naming distinction between CJC-1295 with DAC and without DAC, and what the evidence shows. - [AOD-9604](/peptides/aod-9604): AOD-9604 is a growth hormone fragment studied for obesity. Human trials did not show meaningful benefit at studied exposures, and it is not FDA-approved. - [BPC-157](/peptides/bpc-157): BPC-157 is investigational with human data essentially absent. Learn what FDA's 2023 safety action means and why claims outrun the evidence. - [TB-500](/peptides/tb-500): TB-500 is a research-market name related to thymosin beta-4. Understand the naming, the animal evidence, and what remains unverified in humans. - [KPV](/peptides/kpv): KPV is a minimal alpha-MSH fragment studied for anti-inflammatory and gut signalling in labs. Human evidence remains minimal; learn what's known. - [LL-37](/peptides/ll-37): LL-37 is an endogenous cathelicidin peptide studied in immune research. No approved product exists, and real theoretical risks remain unresolved. - [MOTS-c](/peptides/mots-c): MOTS-c is an investigational mitochondrial-derived peptide studied in animal metabolism research. Human evidence is essentially absent. Read the honest evidence summary. - [5-Amino-1MQ](/peptides/5-amino-1mq): 5-Amino-1MQ is an investigational small-molecule NNMT inhibitor, often marketed alongside peptides. Here is what separates it from a peptide and what evidence actually shows. - [IGF-1 LR3](/peptides/igf-1-lr3): IGF-1 LR3 is a research-grade IGF-1 analogue with real oncologic and hypoglycemia concerns. It is not an approved product for human use. Read the direct evidence summary. - [Epitalon](/peptides/epitalon): Epitalon's longevity literature is dominated by small, older, largely single-group studies and animal work. Read an honest look at what is and isn't known. - [Semax](/peptides/semax): Semax is an investigational peptide studied for cognition and stress response. Learn what is and is not known, and why its Russian registration is not FDA approval. - [Selank](/peptides/selank): Selank is an investigational peptide studied mainly for anxiety-related outcomes. Understand the evidence base, its Russian registration, and open questions. - [DSIP (Delta Sleep-Inducing Peptide)](/peptides/dsip): DSIP's name comes from a 1970s rabbit study. Learn what has and has not been shown about this investigational peptide in human sleep research. - [GHK-Cu (Copper Tripeptide-1)](/peptides/ghk-cu): GHK-Cu is a copper-binding peptide used in cosmetic products. Understand what cosmetic status means, what the research shows, and how topical differs from injectable use. - [Kisspeptin-10](/peptides/kisspeptin-10): An honest look at kisspeptin-10, the research peptide studied for its role upstream of GnRH, LH, and FSH signalling. Not an approved drug product. - [Oxytocin](/peptides/oxytocin): Oxytocin is FDA-approved only for specific obstetric indications. Learn why that approval does not extend to intranasal or bonding-related uses. - [PT-141 (Bremelanotide)](/peptides/pt-141): PT-141, also called bremelanotide, is approved as Vyleesi only for HSDD in premenopausal women. Research-market PT-141 is a different, non-approved product. - [Thymosin Alpha-1](/peptides/thymosin-alpha-1): Thymosin alpha-1 is investigational in the US though approved elsewhere for specific uses. Learn why foreign approval and US compounding status differ. ## Answers (Physician-Reviewed Knowledge Base) - [Answers Home](/answers): Physician-reviewed answers on GLP-1s, medications, side effects, cost, and longevity. - [Why do GLP-1 medications stop working?](/answers/why-do-glp-1-medications-stop-working): Plateaus, dosing, and how physicians restore progress. - [Why do people plateau on semaglutide?](/answers/why-do-people-plateau-on-semaglutide): The biology of plateaus and how to break through. - [Can I drink alcohol on semaglutide or tirzepatide?](/answers/can-i-drink-alcohol-on-semaglutide): Interactions, side effects, and guidance. - [What foods should you avoid on semaglutide?](/answers/what-foods-to-avoid-on-semaglutide): Foods that cause trouble and what to eat instead. - [Does semaglutide cause muscle loss?](/answers/does-semaglutide-cause-muscle-loss): Why it happens and how to protect muscle. - [Do you have to take GLP-1 medications forever?](/answers/do-you-have-to-take-glp-1-forever): Maintenance, tapering, and transitioning off. - [Which is better, semaglutide or tirzepatide?](/answers/semaglutide-vs-tirzepatide-which-is-better): Head-to-head efficacy and how to choose. - [Does frozen semaglutide still work?](/answers/does-frozen-semaglutide-still-work): Why freezing ruins semaglutide and what to do. - [How long can semaglutide be out of the fridge?](/answers/how-long-can-semaglutide-be-out-of-the-fridge): Room-temperature limits and storage. - [Can you freeze Sermorelin?](/answers/can-you-freeze-sermorelin): Storing lyophilized vs reconstituted sermorelin. - [NAD+ side effects](/answers/nad-plus-side-effects): Common effects and who should be cautious. - [Does Medicare cover Wegovy?](/answers/does-medicare-cover-wegovy): 2025 coverage rules and eligibility. - [Does insurance cover semaglutide?](/answers/does-insurance-cover-semaglutide): Brand vs compounded coverage. - [What is Sermorelin?](/answers/what-is-sermorelin): How the peptide works and what it's used for. - [What is NAD+?](/answers/what-is-nad-plus): The coenzyme, why it declines, and how it's used. - [How long does it take for semaglutide to work?](/answers/how-long-does-it-take-for-semaglutide-to-work): Week-by-week timeline and why it's gradual. - [How much weight can you lose on tirzepatide?](/answers/how-much-weight-can-you-lose-on-tirzepatide): Average results and what affects them. - [Why am I not losing weight on semaglutide?](/answers/why-am-i-not-losing-weight-on-semaglutide): Common reasons progress stalls and fixes. - [What happens when you stop taking semaglutide?](/answers/what-happens-when-you-stop-taking-semaglutide): Appetite return, weight regain, and maintenance. - [How much protein do you need on a GLP-1?](/answers/do-you-need-more-protein-on-glp-1): Protein targets to preserve muscle. - [How do you manage nausea on semaglutide?](/answers/how-to-manage-semaglutide-nausea): Practical strategies and when to call your physician. - [Does semaglutide cause hair loss?](/answers/does-semaglutide-cause-hair-loss): Why shedding happens and how to reduce it. - [What is 'Ozempic face'?](/answers/what-is-ozempic-face): Facial fat loss and how to minimize it. - [Can GLP-1 medications cause fatigue?](/answers/can-glp-1-cause-fatigue): Causes of tiredness and what helps. - [Is compounded semaglutide safe?](/answers/is-compounded-semaglutide-safe): What compounding means and how safety is managed. - [What is the starting dose of semaglutide?](/answers/what-is-the-starting-dose-of-semaglutide): Titration and why treatment starts low. - [What is the starting dose of tirzepatide?](/answers/what-is-the-starting-dose-of-tirzepatide): The step-up dosing approach. - [What happens if you miss a dose of semaglutide?](/answers/what-happens-if-you-miss-a-dose-of-semaglutide): Missed-dose rules and long gaps. - [What time of day should you take semaglutide?](/answers/what-time-of-day-should-you-take-semaglutide): Timing, consistency, and changing your day. - [Where do you inject semaglutide?](/answers/where-to-inject-semaglutide): Injection sites and good technique. - [How does online weight-loss treatment work?](/answers/how-does-online-weight-loss-treatment-work): The intake-to-doorstep process. - [Do I qualify for semaglutide?](/answers/do-i-qualify-for-semaglutide): Eligibility and how physicians decide. ## Guides & Tools - [Semaglutide vs Tirzepatide](/guides/semaglutide-vs-tirzepatide): Head-to-head GLP-1 comparison. - [Semaglutide Diet Plan](/guides/semaglutide-diet-plan): Nutrition guidance for GLP-1 patients. - [BMI Calculator](/calculators/bmi): Check your body mass index. - [BMR Calculator](/calculators/bmr): Estimate your basal metabolic rate. - [TDEE Calculator](/calculators/tdee): Estimate total daily energy expenditure. - [Calorie Calculator](/calculators/calories): Daily calorie target estimator. - [Protein Calculator](/calculators/protein): Protein needs for GLP-1 patients. - [Carb Calculator](/calculators/carbs): Daily carbohydrate target estimator. - [Blog](/blog): Articles on GLP-1, weight loss, and wellness. ## Optional - [Privacy Policy](/privacy-policy): How we handle patient data. - [Terms & Conditions](/terms-conditions): Terms of service. - [Billing & Cancellation](/billing-cancellation): Our no-auto-billing renewal policy. - [Partner Program](/partners): Partnership and affiliate opportunities. ## Generated Answers (Sourced From Physician-Reviewed Records) These Answers are generated from GOAL.MD's physician-reviewed source library. They have not received their own page-specific physician review. - [How should patients compare brand-name and compounded GLP-1 costs when using Medicare?](/answers/how-should-patients-compare-brand-name-and-compounded-glp-1-costs-when-using-medicare): Medicare patients should compare their Part D plan's specific out-of-pocket costs for brand-name GLP-1s, if covered, against the fixed monthly price o - [What should patients compare before choosing a provider for tirzepatide injections?](/answers/what-should-patients-compare-before-choosing-a-provider-for-tirzepatide-injections): Compare providers on physician supervision, medication sourcing from licensed U.S. pharmacies, transparent pricing, and comprehensive clinical support - [What pregnancy, fertility, and contraception questions should be discussed before semaglutide?](/answers/what-pregnancy-fertility-and-contraception-questions-should-be-discussed-before-semaglutid): Discuss pregnancy plans, fertility history, and contraception before semaglutide. The drug must be stopped at least 2 months before trying to conceive - [Can GLP-1 coverage under Medicare change after a patient loses weight?](/answers/can-glp-1-coverage-under-medicare-change-after-a-patient-loses-weight): Yes, Medicare GLP-1 coverage can change. Continued coverage depends on the drug's medically approved use, like managing diabetes or cardiovascular ris - [Are consultations, labs, supplies, and shipping usually separate from medication under Medicare?](/answers/are-consultations-labs-supplies-and-shipping-usually-separate-from-medication-under-medica): Yes, under Medicare, medical services like consultations and labs are billed separately from prescription medications, which are covered under differe - [Which prescription drugs and supplements deserve review before starting semaglutide?](/answers/which-prescription-drugs-and-supplements-deserve-review-before-starting-semaglutide): Certain diabetes drugs (insulin, sulfonylureas), oral medications, and some supplements warrant review with your physician before starting semaglutide - [What determines the cash price of oral Wegovy, including pharmacy and delivery fees?](/answers/what-determines-the-cash-price-of-oral-wegovy-including-pharmacy-and-delivery-fees): Wegovy is an injectable, not an oral medication. Its cash price is determined by the manufacturer's list price, pharmacy fees, and any available savin - [What should a patient tell the anesthesia team before surgery or sedation while using tirzepatide?](/answers/what-should-a-patient-tell-the-anesthesia-team-before-surgery-or-sedation-while-using-tirz): Patients must tell their anesthesia team they use tirzepatide. The drug delays stomach emptying, increasing the risk of aspiration during surgery or s - [How should patients compare telehealth GLP-1 providers when relying on an employer health plan?](/answers/how-should-patients-compare-telehealth-glp-1-providers-when-relying-on-an-employer-health-): Compare telehealth GLP-1 providers by their insurance support for prior authorizations, formulary expertise, clinical model, and total cost transparen - [Which prescription drugs and supplements deserve review before starting tirzepatide?](/answers/which-prescription-drugs-and-supplements-deserve-review-before-starting-tirzepatide): Tirzepatide requires review of insulin, sulfonylureas, and oral drugs, especially contraceptives, as it can increase hypoglycemia risk and alter absor - [What warning signs suggest an online offer for Wegovy may be misleading or unsafe?](/answers/what-warning-signs-suggest-an-online-offer-for-wegovy-may-be-misleading-or-unsafe): Warning signs for unsafe online Wegovy include no prescription requirement, unusually low prices, and claims of being a 'generic' or 'research' versio - [What questions prevent surprise fees in a GLP-1 program paid through Medicare?](/answers/what-questions-prevent-surprise-fees-in-a-glp-1-program-paid-through-medicare): Ask about your Part D plan's formulary, prior authorization rules, drug indication, and your costs during each coverage phase, including the 'donut ho - [Who is at risk of low blood sugar on tirzepatide, and what are the warning signs?](/answers/who-is-at-risk-of-low-blood-sugar-on-tirzepatide-and-what-are-the-warning-signs): Patients taking tirzepatide with insulin or sulfonylureas are at the highest risk of low blood sugar. Warning signs include shakiness, sweating, and c - [What options may exist if GLP-1 coverage through Medicaid ends during treatment?](/answers/what-options-may-exist-if-glp-1-coverage-through-medicaid-ends-during-treatment): If Medicaid GLP-1 coverage ends, options include appeals, manufacturer programs, or discussing physician-supervised compounded medications with a prov - [What should be included when comparing the total monthly cost of GLP-1 care with Medicaid?](/answers/what-should-be-included-when-comparing-the-total-monthly-cost-of-glp-1-care-with-medicaid): Comparing GLP-1 care costs with Medicaid involves the drug's price, co-pays, prior authorization hurdles, and costs for physician visits and labs. - [What belongs on a transparent pricing page for an online GLP-1 provider?](/answers/what-belongs-on-a-transparent-pricing-page-for-an-online-glp-1-provider): A transparent GLP-1 pricing page lists all costs upfront: medication, consultations, shipping, and supplies, and discloses provider and pharmacy crede - [How should patients compare telehealth GLP-1 providers when relying on cash-pay treatment?](/answers/how-should-patients-compare-telehealth-glp-1-providers-when-relying-on-cash-pay-treatment): When comparing cash-pay telehealth GLP-1 providers, patients should evaluate medication sourcing, physician access, total cost transparency, and pharm - [Which sales, prescribing, and billing practices are red flags in an online GLP-1 provider?](/answers/which-sales-prescribing-and-billing-practices-are-red-flags-in-an-online-glp-1-provider): Red flags for online GLP-1 providers include no live video consults, prescribing without labs, sourcing from unlicensed pharmacies, and unclear pricin - [What follow-up access should patients expect after enrolling with an online GLP-1 provider?](/answers/what-follow-up-access-should-patients-expect-after-enrolling-with-an-online-glp-1-provider): Patients should expect scheduled physician check-ins, on-demand access to a care team for questions, and periodic lab work to monitor progress and saf - [What pregnancy, fertility, and contraception questions should be discussed before a compounded GLP-1?](/answers/what-pregnancy-fertility-and-contraception-questions-should-be-discussed-before-a-compound): Stop GLP-1s at least 2 months before pregnancy. Discuss backup contraception as GLP-1s can reduce oral pill efficacy. Fertility effects are unknown. - [How should patients compare telehealth GLP-1 providers when relying on Medicaid?](/answers/how-should-patients-compare-telehealth-glp-1-providers-when-relying-on-medicaid): Patients on Medicaid must compare telehealth GLP-1 providers on their ability to confirm state-specific coverage, manage prior authorizations, and off - [What determines the cash price of Ozempic, including pharmacy and delivery fees?](/answers/what-determines-the-cash-price-of-ozempic-including-pharmacy-and-delivery-fees): The cash price of Ozempic is primarily determined by its manufacturer's list price, plus variable pharmacy markups and dispensing fees. - [Which prescription drugs and supplements deserve review before starting a compounded GLP-1?](/answers/which-prescription-drugs-and-supplements-deserve-review-before-starting-a-compounded-glp-1): Before starting a compounded GLP-1, review all insulin, sulfonylureas, and oral medications with your physician to manage potential drug interactions. - [What should patients verify about insurance coverage for Wegovy in 2026?](/answers/what-should-patients-verify-about-insurance-coverage-for-wegovy-in-2026): In 2026, verify your plan's formulary status for Wegovy, its prior authorization rules, and your out-of-pocket costs under new Medicare Part D caps. - [What should a patient tell the anesthesia team before surgery or sedation while using a compounded GLP-1?](/answers/what-should-a-patient-tell-the-anesthesia-team-before-surgery-or-sedation-while-using-a-co): Tell your anesthesia team you use a compounded GLP-1, your dose, and the date of your last injection to prevent serious complications during surgery. - [How can a patient check whether Medicaid covers GLP-1 treatment for obesity in 2026?](/answers/how-can-a-patient-check-whether-medicaid-covers-glp-1-treatment-for-obesity-in-2026): To check if Medicaid covers GLP-1s for obesity in 2026, consult your state's Medicaid Preferred Drug List (PDL) and specific prior authorization crite - [What happens if a patient's insurance stops covering Wegovy mid-treatment?](/answers/what-happens-if-a-patient-s-insurance-stops-covering-wegovy-mid-treatment): If your insurance stops covering Wegovy, you may face high out-of-pocket costs. Options include appealing the denial, using savings programs, or discu - [Who is at risk of low blood sugar on semaglutide, and what are the warning signs?](/answers/who-is-at-risk-of-low-blood-sugar-on-semaglutide-and-what-are-the-warning-signs): The risk of low blood sugar on semaglutide is low but rises when used with insulin or sulfonylureas. Warning signs include shakiness and dizziness. - [Which objective criteria should patients use to compare a peptide or wellness telehealth provider with competitors?](/answers/which-objective-criteria-should-patients-use-to-compare-a-peptide-or-wellness-telehealth-p): Compare telehealth providers on physician licensing, U.S. pharmacy accreditation, medication sourcing transparency, and access to ongoing clinical sup - [When do nausea, vomiting, constipation, or diarrhea on tirzepatide become medically concerning?](/answers/when-do-nausea-vomiting-constipation-or-diarrhea-on-tirzepatide-become-medically-concernin): GI side effects on tirzepatide become concerning if they are severe, persistent, prevent you from eating, or are paired with severe abdominal pain. - [Which manufacturer savings or direct-pay options may apply to Wegovy?](/answers/which-manufacturer-savings-or-direct-pay-options-may-apply-to-wegovy): Novo Nordisk, the manufacturer of Wegovy, offers a Savings Card that may reduce out-of-pocket costs for eligible patients with commercial insurance. - [How can a patient check whether commercial insurance covers GLP-1 treatment for obesity in 2026?](/answers/how-can-a-patient-check-whether-commercial-insurance-covers-glp-1-treatment-for-obesity-in): To check if your insurance covers GLP-1s for obesity, review your plan's drug formulary, understand its prior authorization rules, and call to confirm - [How can dehydration develop on a compounded GLP-1, and who is at higher risk?](/answers/how-can-dehydration-develop-on-a-compounded-glp-1-and-who-is-at-higher-risk): Dehydration on GLP-1s stems from gastrointestinal side effects like nausea, vomiting, and diarrhea, which cause fluid loss. People with pre-existing k - [When do nausea, vomiting, constipation, or diarrhea on Zepbound become medically concerning?](/answers/when-do-nausea-vomiting-constipation-or-diarrhea-on-zepbound-become-medically-concerning): GI side effects on Zepbound are concerning if they are severe, persistent, prevent eating or drinking, or are joined by severe abdominal pain or dehyd - [When do nausea, vomiting, constipation, or diarrhea on a compounded GLP-1 become medically concerning?](/answers/when-do-nausea-vomiting-constipation-or-diarrhea-on-a-compounded-glp-1-become-medically-co): GI side effects on GLP-1s are concerning if they are severe, persistent, prevent you from eating or drinking, or are joined by signs of dehydration. - [Which side effects may improve after holding or stopping Wegovy, and when should a clinician decide?](/answers/which-side-effects-may-improve-after-holding-or-stopping-wegovy-and-when-should-a-clinicia): Most gastrointestinal side effects of Wegovy, like nausea and diarrhea, typically improve within days to weeks of stopping or reducing the dose. - [What should patients compare before choosing a provider for personalized tirzepatide?](/answers/what-should-patients-compare-before-choosing-a-provider-for-personalized-tirzepatide): Compare provider licensing, pharmacy standards, medication sourcing, program inclusions, and total cost before choosing a personalized tirzepatide pro - [What should patients compare before choosing a provider for oral semaglutide?](/answers/what-should-patients-compare-before-choosing-a-provider-for-oral-semaglutide): When choosing a provider for oral semaglutide, patients should compare physician supervision, medication sourcing, program structure, and pricing tran - [What should a patient tell the anesthesia team before surgery or sedation while using semaglutide?](/answers/what-should-a-patient-tell-the-anesthesia-team-before-surgery-or-sedation-while-using-sema): Inform your anesthesia team you use semaglutide, the date of your last dose, and strictly follow their preoperative fasting instructions to reduce ris - [How should patients compare brand-name and compounded GLP-1 costs when using Medicaid?](/answers/how-should-patients-compare-brand-name-and-compounded-glp-1-costs-when-using-medicaid): Medicaid may cover brand-name GLP-1s like Wegovy or Zepbound for a low copay, but prior authorization is common. Compounded GLP-1s are not covered. - [Can GLP-1 coverage under Medicaid change after a patient loses weight?](/answers/can-glp-1-coverage-under-medicaid-change-after-a-patient-loses-weight): Yes, Medicaid may stop covering GLP-1s if weight loss causes you to no longer meet the initial BMI criteria required for prior authorization. - [Which side effects may improve after holding or stopping Zepbound, and when should a clinician decide?](/answers/which-side-effects-may-improve-after-holding-or-stopping-zepbound-and-when-should-a-clinic): Most Zepbound side effects, like nausea and diarrhea, resolve within days to weeks of stopping or lowering the dose under physician supervision. - [How should patients compare telehealth GLP-1 providers when relying on commercial insurance?](/answers/how-should-patients-compare-telehealth-glp-1-providers-when-relying-on-commercial-insuranc): Compare GLP-1 providers by their insurance support, fee structures, scope of care, and medication options (branded vs. compounded). - [What documentation is commonly needed for GLP-1 prior authorization under commercial insurance?](/answers/what-documentation-is-commonly-needed-for-glp-1-prior-authorization-under-commercial-insur): Insurers typically require medical records proving a qualifying diagnosis, like type 2 diabetes or a specific BMI, and documentation of failed alterna - [How can dehydration develop on Wegovy, and who is at higher risk?](/answers/how-can-dehydration-develop-on-wegovy-and-who-is-at-higher-risk): Wegovy can cause dehydration through gastrointestinal side effects like nausea, vomiting, and diarrhea, which increase fluid loss and reduce fluid int - [What pregnancy, fertility, and contraception questions should be discussed before tirzepatide?](/answers/what-pregnancy-fertility-and-contraception-questions-should-be-discussed-before-tirzepatid): Before starting tirzepatide, discuss stopping it 2+ months before a planned pregnancy, its impact on oral contraceptives, and potential fertility chan - [When do nausea, vomiting, constipation, or diarrhea on Wegovy become medically concerning?](/answers/when-do-nausea-vomiting-constipation-or-diarrhea-on-wegovy-become-medically-concerning): GI side effects on Wegovy are concerning if severe, persistent, prevent eating or drinking, or are paired with signs of dehydration or intense abdomin - [How should patients compare telehealth GLP-1 providers when relying on Medicare?](/answers/how-should-patients-compare-telehealth-glp-1-providers-when-relying-on-medicare): Medicare Part D generally denies coverage for GLP-1 drugs prescribed for weight loss, so patients must compare provider fees and program models. - [When do nausea, vomiting, constipation, or diarrhea on semaglutide become medically concerning?](/answers/when-do-nausea-vomiting-constipation-or-diarrhea-on-semaglutide-become-medically-concernin): GI issues on semaglutide are concerning if severe, persistent, or cause dehydration, intense pain, or an inability to keep down food or liquids. - [What determines the cash price of Wegovy, including pharmacy and delivery fees?](/answers/what-determines-the-cash-price-of-wegovy-including-pharmacy-and-delivery-fees): The cash price of Wegovy is set by its manufacturer's list price, pharmacy markups and fees, and the application of any discount or savings programs. - [Which side effects may improve after holding or stopping tirzepatide, and when should a clinician decide?](/answers/which-side-effects-may-improve-after-holding-or-stopping-tirzepatide-and-when-should-a-cli): Most gastrointestinal side effects of tirzepatide, like nausea, improve within days to weeks of stopping the medication as it clears from your system. - [How can dehydration develop on semaglutide, and who is at higher risk?](/answers/how-can-dehydration-develop-on-semaglutide-and-who-is-at-higher-risk): Semaglutide's common gastrointestinal side effects, like nausea, vomiting, and diarrhea, can lead to fluid loss and cause dehydration in some individu - [Which side effects may improve after holding or stopping semaglutide, and when should a clinician decide?](/answers/which-side-effects-may-improve-after-holding-or-stopping-semaglutide-and-when-should-a-cli): Gastrointestinal side effects of semaglutide like nausea typically improve after discontinuation. A clinician decides to hold or stop based on symptom - [What should patients compare before choosing a provider for semaglutide injections?](/answers/what-should-patients-compare-before-choosing-a-provider-for-semaglutide-injections): Compare providers on physician supervision, medication sourcing from licensed U.S. pharmacies, transparent pricing, and comprehensive clinical support - [What options may exist if GLP-1 coverage through Medicare ends during treatment?](/answers/what-options-may-exist-if-glp-1-coverage-through-medicare-ends-during-treatment): If Medicare stops covering your GLP-1, options include appealing the denial, seeking patient assistance, or discussing alternatives like compounded me - [What should be included when comparing the total monthly cost of GLP-1 care with Medicare?](/answers/what-should-be-included-when-comparing-the-total-monthly-cost-of-glp-1-care-with-medicare): Total monthly GLP-1 cost on Medicare includes your Part D premium, deductible, copay/coinsurance, and any costs incurred during the coverage gap. - [How can a patient and clinician respond to a GLP-1 denial under Medicare?](/answers/how-can-a-patient-and-clinician-respond-to-a-glp-1-denial-under-medicare): Respond to a GLP-1 denial from Medicare by filing a formal appeal with a letter of medical necessity or exploring non-covered, physician-supervised op - [Which manufacturer savings or direct-pay options may apply to Ozempic?](/answers/which-manufacturer-savings-or-direct-pay-options-may-apply-to-ozempic): Eligible, commercially insured patients can use the Ozempic® Savings Card, while uninsured patients may qualify for the Novo Nordisk Patient Assistanc - [How can a patient check whether Medicare covers GLP-1 treatment for obesity in 2026?](/answers/how-can-a-patient-check-whether-medicare-covers-glp-1-treatment-for-obesity-in-2026): As of 2024, Medicare law prohibits Part D plans from covering weight loss drugs, but patients should check their 2026 plan formulary for any policy ch - [Which objective criteria should patients use to compare an online GLP-1 provider with competitors?](/answers/which-objective-criteria-should-patients-use-to-compare-an-online-glp-1-provider-with-comp): Compare online GLP-1 providers based on their clinical model, medication sourcing from licensed U.S. pharmacies, price transparency, and ongoing physi - [What happens if a patient's insurance stops covering Ozempic mid-treatment?](/answers/what-happens-if-a-patient-s-insurance-stops-covering-ozempic-mid-treatment): If insurance stops covering Ozempic, patients may face high costs but have options, including appeals, manufacturer savings programs, and alternative - [How might tirzepatide injections affect appetite, glucose, waist size, and cardiometabolic risk?](/answers/how-might-tirzepatide-injections-affect-appetite-glucose-waist-size-and-cardiometabolic-ri): Tirzepatide reduces appetite, lowers blood glucose, significantly decreases waist size, and improves several key cardiometabolic risk factors. - [What should a patient tell the anesthesia team before surgery or sedation while using Wegovy?](/answers/what-should-a-patient-tell-the-anesthesia-team-before-surgery-or-sedation-while-using-wego): Inform your anesthesia team that you use Wegovy and the date of your last dose, as it can increase aspiration risk by delaying stomach emptying. - [What pregnancy, fertility, and contraception questions should be discussed before Wegovy?](/answers/what-pregnancy-fertility-and-contraception-questions-should-be-discussed-before-wegovy): Before starting Wegovy, discuss stopping the medication at least two months before a planned pregnancy and the need for effective contraception during - [What should patients verify about insurance coverage for Ozempic in 2026?](/answers/what-should-patients-verify-about-insurance-coverage-for-ozempic-in-2026): For Ozempic coverage in 2026, verify its place on your insurance formulary, its prior authorization rules, and your total out-of-pocket costs. - [What pregnancy, fertility, and contraception questions should be discussed before Zepbound?](/answers/what-pregnancy-fertility-and-contraception-questions-should-be-discussed-before-zepbound): Discuss stopping Zepbound 2 months before a planned pregnancy, its potential effect on oral birth control, and the need to report a pregnancy immediat - [What warning signs suggest an online offer for Ozempic may be misleading or unsafe?](/answers/what-warning-signs-suggest-an-online-offer-for-ozempic-may-be-misleading-or-unsafe): Warning signs of unsafe Ozempic offers include no prescription requirement, prices far below retail, and packaging that differs from the authentic pro - [Can GLP-1 coverage under commercial insurance change after a patient loses weight?](/answers/can-glp-1-coverage-under-commercial-insurance-change-after-a-patient-loses-weight): Yes, commercial insurance can stop covering GLP-1s after weight loss due to re-authorization rules that may no longer see the treatment as medically n - [Who is at risk of low blood sugar on Zepbound, and what are the warning signs?](/answers/who-is-at-risk-of-low-blood-sugar-on-zepbound-and-what-are-the-warning-signs): Patients using Zepbound with insulin or sulfonylureas are at the highest risk for low blood sugar (hypoglycemia), with warning signs like shakiness an - [Which prescription drugs and supplements deserve review before starting Zepbound?](/answers/which-prescription-drugs-and-supplements-deserve-review-before-starting-zepbound): Before starting Zepbound, review all oral drugs, insulin, sulfonylureas, and certain supplements with your physician due to potential interactions. - [What should a patient tell the anesthesia team before surgery or sedation while using Zepbound?](/answers/what-should-a-patient-tell-the-anesthesia-team-before-surgery-or-sedation-while-using-zepb): Tell your anesthesia team you use Zepbound, the date of your last dose, and if you have nausea, vomiting, or abdominal bloating, as the drug can delay - [What determines the cash price of the Zepbound KwikPen, including pharmacy and delivery fees?](/answers/what-determines-the-cash-price-of-the-zepbound-kwikpen-including-pharmacy-and-delivery-fee): The cash price of a Zepbound KwikPen is based on the manufacturer's list price, pharmacy fees, and eligibility for Lilly's Zepbound Savings Card progr - [What options may exist if GLP-1 coverage through commercial insurance ends during treatment?](/answers/what-options-may-exist-if-glp-1-coverage-through-commercial-insurance-ends-during-treatmen): If GLP-1 insurance coverage ends, options include appealing the decision, applying for manufacturer savings programs, or exploring physician-supervise - [What questions prevent surprise fees in a GLP-1 program paid through commercial insurance?](/answers/what-questions-prevent-surprise-fees-in-a-glp-1-program-paid-through-commercial-insurance): To prevent surprise fees for GLP-1s, ask your insurer about your formulary, deductible, copay, and prior authorization rules before starting treatment - [How can dehydration develop on Zepbound, and who is at higher risk?](/answers/how-can-dehydration-develop-on-zepbound-and-who-is-at-higher-risk): Zepbound may cause dehydration through gastrointestinal side effects like nausea, vomiting, and diarrhea, which lead to significant fluid and electrol - [What determines the cash price of Zepbound, including pharmacy and delivery fees?](/answers/what-determines-the-cash-price-of-zepbound-including-pharmacy-and-delivery-fees): The cash price of Zepbound is determined by its wholesale list price, individual pharmacy markups and fees, and eligibility for manufacturer savings p - [How should patients compare brand-name and compounded GLP-1 costs when using commercial insurance?](/answers/how-should-patients-compare-brand-name-and-compounded-glp-1-costs-when-using-commercial-in): Compare costs by checking your insurance formulary for brand-name GLP-1s, calculating your deductible and copay, and weighing it against the all-inclu - [Are consultations, labs, supplies, and shipping usually separate from medication under commercial insurance?](/answers/are-consultations-labs-supplies-and-shipping-usually-separate-from-medication-under-commer): Yes, under commercial insurance, costs for consultations, lab work, supplies, and shipping are typically billed separately from the medication's copay - [What should be included when comparing the total monthly cost of GLP-1 care with commercial insurance?](/answers/what-should-be-included-when-comparing-the-total-monthly-cost-of-glp-1-care-with-commercia): Total GLP-1 cost includes the drug copay, deductible, and coinsurance, plus expenses for provider visits, lab tests, and required supplies. - [How can a patient and clinician respond to a GLP-1 denial under commercial insurance?](/answers/how-can-a-patient-and-clinician-respond-to-a-glp-1-denial-under-commercial-insurance): Respond to a GLP-1 denial by understanding the reason, then working with your clinician to submit a formal appeal with detailed medical documentation. - [How can dehydration develop on tirzepatide, and who is at higher risk?](/answers/how-can-dehydration-develop-on-tirzepatide-and-who-is-at-higher-risk): Tirzepatide can cause dehydration through GI side effects like nausea, vomiting, and diarrhea, which lead to significant fluid and electrolyte loss. - [Who is at risk of low blood sugar on Wegovy, and what are the warning signs?](/answers/who-is-at-risk-of-low-blood-sugar-on-wegovy-and-what-are-the-warning-signs): Patients with type 2 diabetes taking insulin or a sulfonylurea with Wegovy are at the highest risk for low blood sugar (hypoglycemia). - [What documentation is commonly needed for GLP-1 prior authorization under Medicare?](/answers/what-documentation-is-commonly-needed-for-glp-1-prior-authorization-under-medicare): Medicare prior authorization for GLP-1s typically requires documented proof of a type 2 diabetes diagnosis, recent lab work, and a history of failed p - [Which prescription drugs and supplements deserve review before starting Wegovy?](/answers/which-prescription-drugs-and-supplements-deserve-review-before-starting-wegovy): Before starting Wegovy, review all oral drugs, insulin, and sulfonylureas with your physician, as Wegovy can alter their absorption and increase hypog ## Peptide Education Library Education-only pages. Regulatory status is stated per ingredient and must not be summarised as FDA approval. Machine-readable facts for these pages: https://goal.md/peptides/catalog.json - [Peptide Education Library](/peptides): Hub for peptide ingredient education, organized by regulatory status and research area. - [Peptide Ingredients Index](/peptides/ingredients): Directory of every released peptide ingredient page, with regulatory status labeled on each entry. - [5-Amino-1MQ](/peptides/5-amino-1mq): Investigational. 5-Amino-1MQ is a synthetic small molecule studied as an inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase), which sits at a crossroads of cellular energy metabolism. It is frequently sold alongside peptides in research-chemical marketplaces, but chemically it is not a peptide at all, and that distinction affects how it is manufactured, analyzed, and regulated. Research to date is almost entirely limited to cultured cells and rodents. No published human trial data establish safety or benefit in people. - [AOD-9604](/peptides/aod-9604): Investigational. AOD-9604 is a fragment of the human growth hormone molecule, corresponding to amino acids 176 to 191, that was specifically developed and tested as a potential treatment for obesity. Human clinical trials conducted for that purpose did not demonstrate a meaningful weight-loss or fat-loss effect at the exposures studied, and the substance was not approved as a result. It is not an FDA-approved drug product, and its history is a useful, direct illustration of how a peptide can advance through human testing and still fail to show worthwhile benefit. This page states that outcome plainly rather than treating AOD-9604 as an open or promising question. - [BPC-157](/peptides/bpc-157): Investigational. BPC-157 is a synthetic peptide derived from a fragment of a protein found in gastric juice, studied almost exclusively in animal and cell models of tissue and gut signalling. It is not an FDA-approved drug product, and in 2023 the FDA identified it as a bulk substance raising significant safety concerns for compounding, which limits how it can lawfully be prepared. Enthusiasm for BPC-157 online is driven overwhelmingly by preclinical findings and anecdote rather than by controlled human trials. Patients who ask about it should understand that its popularity currently exceeds the strength of its human evidence base by a wide margin. - [CJC-1295](/peptides/cjc-1295): Investigational. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) studied for its potential to stimulate growth hormone release. It exists under two related names describing different chemical formulations, one with a drug affinity complex (DAC) and one without, often called Modified GRF 1-29; this is a naming and formulation distinction, not a statement about how either is used. Neither form is an FDA-approved drug product, and human evidence for either remains limited. This page explains the naming clearly and separates it from any claim of approval or established benefit. - [DSIP (Delta Sleep-Inducing Peptide)](/peptides/dsip): Investigational. Delta sleep-inducing peptide, or DSIP, is a short peptide first isolated from the blood of rabbits in the 1970s during studies of sleep induction, a discovery that gave it a name suggesting a sleep-promoting function it has not been shown to reliably reproduce in humans. It is not an FDA-approved drug product, and despite decades of subsequent research, the human sleep evidence is inconsistent and largely limited to small, older studies. Patients often ask about DSIP assuming its name reflects an established mechanism, when in fact the name reflects a single historical animal observation. Understanding that history is essential to interpreting any claim made about this peptide today. - [Epitalon](/peptides/epitalon): Investigational. Epitalon is a synthetic tetrapeptide modeled on a substance isolated from the pineal gland, studied for decades primarily by a small group of researchers investigating pineal biology, telomerase activity, and aging in animal and limited human cohorts. The literature discussing it is notable for its age and its concentration among a small number of research groups rather than broad, independent replication. It is not an approved product, and describing it as capable of slowing biological aging goes beyond what this literature can support. - [GHK-Cu (Copper Tripeptide-1)](/peptides/ghk-cu): Cosmetic or topical context. GHK-Cu is a naturally occurring copper-binding tripeptide most commonly encountered as an ingredient in topical cosmetic products marketed for skin appearance. Its presence in a cosmetic formulation reflects FDA oversight of ingredient safety and labeling, not FDA review of whether the product delivers the cosmetic benefit advertised. Most published research is laboratory-based or comes from small, often industry-funded human studies of specific formulations, so results from one product cannot be assumed to apply to another. Injectable use of GHK-Cu is a materially different and separately regulated matter from topical cosmetic use and is not addressed by cosmetic research. - [IGF-1 LR3](/peptides/igf-1-lr3): Investigational. IGF-1 LR3 is a laboratory-engineered analogue of insulin-like growth factor 1, modified to resist degradation for use as a research reagent in cell culture, not as a therapeutic product. It is not an approved product for human use, and it should not be treated as a variant of an approved medicine. Because it acts on growth factor signalling, it raises genuine concerns about effects on cell proliferation and about severe blood sugar drops, concerns that are taken seriously in the scientific literature on IGF-1 biology generally. There is no controlled human trial establishing a safety profile for this specific analogue. - [Ipamorelin](/peptides/ipamorelin): Investigational. Ipamorelin is a synthetic peptide studied as a selective growth hormone secretagogue, meaning it is proposed to stimulate growth hormone release without the broader hormonal effects seen with some older secretagogues. It is not an FDA-approved drug product, and its position in the compounding market has been directly shaped by FDA decisions about which bulk drug substances compounding pharmacies may legally use. Those decisions have changed over time, so any statement about current compounding availability needs verification rather than assumption. This page focuses on that regulatory reality alongside what is and is not known from the research. - [Kisspeptin-10](/peptides/kisspeptin-10): Investigational. Kisspeptin-10 is a fragment of the kisspeptin peptide family studied for its role as an upstream trigger of the reproductive hormone cascade, sitting above GnRH, LH, and FSH release. It is not an FDA-approved drug product and no approved medicine is built on it. Researchers have used it mainly as an experimental probe to understand how the hypothalamus signals the pituitary and gonads, including in small human physiology studies. Patients typically ask about it in the context of reproductive hormone or libido-related questions, but the evidence base remains investigational and narrow. - [KPV](/peptides/kpv): Investigational. KPV is the smallest active fragment of alpha-melanocyte-stimulating hormone, consisting of just three amino acids: lysine, proline, and valine. Laboratory and animal research has focused on its apparent anti-inflammatory signalling, particularly in models of intestinal inflammation, independent of the pigmentation and appetite pathways associated with full-length alpha-MSH. It is not an FDA-approved drug product, and published human data are minimal. Interest in KPV should be understood as interest in an actively researched signalling fragment, not an established anti-inflammatory therapy. - [LL-37](/peptides/ll-37): Investigational. LL-37 is the only cathelicidin-family antimicrobial peptide produced naturally by the human body, generated by immune cells and skin as part of innate host defence against microbes. It is studied extensively in laboratory settings for its antimicrobial and immune-modulating properties, but it is not an FDA-approved drug product, and no approved therapeutic version exists. Unlike many investigational peptides discussed for enhancement or recovery, LL-37 research carries a genuine two-sided profile: the same immune-activating signalling that makes it interesting also raises real theoretical concerns about excessive inflammation and autoimmune-like activity. This page focuses on explaining that duality rather than presenting LL-37 as a benign or emerging option. - [MOTS-c](/peptides/mots-c): Investigational. MOTS-c is a short peptide encoded within the mitochondrial genome that has drawn research interest as a signal linking mitochondrial function to whole-body metabolism. Almost everything known about it comes from mouse and cell-culture experiments rather than from people. It is not an approved drug, and no clinical trial has established what it does when given to humans. Claims about fat loss or longevity benefit in people are not supported by the current published record. - [Oxytocin](/peptides/oxytocin): FDA-approved for a specific indication. Oxytocin is a naturally occurring hormone and neuropeptide, and an injectable form is FDA-approved strictly for specific obstetric indications administered in a clinical setting. That approval does not extend to intranasal oxytocin sprays or to any use aimed at mood, bonding, intimacy, or general wellness, which remain the subject of investigational research rather than approved medicine. Separately from any clinical use, oxytocin has drawn substantial scientific interest for its proposed role in social bonding and trust behaviour, largely from animal studies and small human trials. Patients should understand that these are two distinct conversations: an approved obstetric drug, and an investigational research literature that has not produced an approved product for behavioural or sexual-health use. - [PT-141 (Bremelanotide)](/peptides/pt-141): FDA-approved for a specific indication. PT-141 is the research name for bremelanotide, a melanocortin receptor agonist, and it exists in two very different forms that patients frequently conflate. One form, marketed under the brand name Vyleesi, is FDA-approved specifically for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The other, sold on the research market as PT-141, is not the approved Vyleesi product, is not FDA-approved for any use, and is not the same as a compounded preparation supervised by a pharmacist. Approval does not extend to men or to postmenopausal women under either name, and understanding this distinction is essential before considering any use. - [Selank](/peptides/selank): Investigational. Selank is a synthetic peptide derived from tuftsin, an immune-signalling peptide fragment, and has been studied predominantly by Russian researchers for anxiety-related outcomes. It holds a Russian medicine registration for anxiety indications, a status specific to that country's regulatory process and not recognized by or transferable to the FDA. Patients typically raise Selank in the context of stress and anxiety rather than cognition broadly. The available human evidence remains concentrated in a small number of research groups and has not been independently replicated at scale under modern international trial standards. - [Semax](/peptides/semax): Investigational. Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH) that has been studied in Russia for decades and is registered there as a medicine for certain neurological indications. It is not an FDA-approved drug product in the United States, and its Russian registration does not establish safety or effectiveness under US regulatory standards. Patient interest generally centers on attention, mental fatigue, and stress recovery. The English-language human evidence base is thin compared to the Russian literature, and independent replication under modern trial standards is limited. - [TB-500](/peptides/tb-500): Investigational. TB-500 is the name used in the research-chemical marketplace for a synthetic peptide related to a short active region of thymosin beta-4, a naturally occurring protein involved in cell movement and structural signalling within cells. It is not an FDA-approved drug product, and "TB-500" itself is not a scientifically standardized name, which means products sold under it are not independently verified to contain what their labels claim. Most available evidence comes from animal studies of tissue and vascular signalling rather than controlled human trials. Patients researching it should distinguish between the biology of thymosin beta-4 as studied in labs and the unregulated commercial products marketed as TB-500. - [Tesamorelin](/peptides/tesamorelin): FDA-approved for a specific indication. Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue with one specific FDA approval: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That approval is narrow and does not extend to general weight loss, general body composition change, athletic performance, or longevity goals in people without this diagnosis. Any other use is off-label. This page separates what the approval actually covers from what patients often hope it means. - [Thymosin Alpha-1](/peptides/thymosin-alpha-1): Investigational. Thymosin alpha-1 is a naturally occurring thymic peptide studied for its role in modulating immune cell activity, and it carries a genuinely split regulatory story. In the United States it remains investigational and is not an FDA-approved drug product, while in some other countries it is registered or approved under brand names such as Zadaxin for specific indications. That foreign status does not transfer to the United States, and separately, the FDA's review of thymosin alpha-1 under the list of bulk substances eligible for 503A compounding has directly affected whether US compounding pharmacies can prepare it, a status that changes over time and needs to be verified before any discussion proceeds. - [Peptide Stacks](/peptides/stacks): Directory of named multi-ingredient peptide stacks, each with combination-evidence framing. - [Adonix](/peptides/stacks/adonix): Adonix is a named combination of tesamorelin, ipamorelin, AOD-9604, and MOTS-C. Its components sit in growth hormone and metabolic signalling research. No controlled human trial of this specific four-part combination was identified, so anything said about it is extrapolated from work on the individual substances. - [APEX](/peptides/stacks/apex): APEX is a named combination of tesamorelin, CJC-1295, ipamorelin, and BPC-157. Three components relate to growth hormone signalling and one comes from tissue repair research. No controlled human study of this combination was identified, so the page separates what is known about each component from what is unknown about the group. - [Atlas](/peptides/stacks/atlas): Atlas is a named combination of CJC-1295, ipamorelin, tesamorelin, and IGF-1 LR3. Three components act upstream of growth hormone release and the fourth is an insulin-like growth factor analogue that acts downstream. No controlled human study of this combination was identified, and the presence of IGF-1 LR3 raises specific safety questions that this page states directly. - [Bodhi](/peptides/stacks/bodhi): Bodhi is a named combination of semax, selank, BPC-157, and KPV. Two components are approved as medicines in Russia but not in the United States, and two come from tissue and inflammatory signalling research. No study of the combination was identified. - [Empress](/peptides/stacks/empress): Empress is a named combination of MOTS-C, BPC-157, GHK-Cu, and kisspeptin-10. It spans mitochondrial, tissue repair, copper peptide, and reproductive hormone signalling research. No study of the combination was identified, and the inclusion of a reproductive signalling peptide adds specific considerations. - [Fountain of Youth](/peptides/stacks/fountain-of-youth): Fountain of Youth is a named combination of GHK-Cu, BPC-157, TB-500, and epitalon. The components come from copper peptide, tissue signalling, and pineal peptide research. No human study of the combination was identified, and nothing here has been shown to affect human aging or lifespan. - [Hypnos](/peptides/stacks/hypnos): Hypnos is a named combination of DSIP, selank, CJC-1295, and ipamorelin. It pairs a peptide named for sleep research with an anxiety-context neuropeptide and two growth hormone releasing approaches. No study of the combination was identified. - [Inferno](/peptides/stacks/inferno): Inferno is a named combination of AOD-9604, CJC-1295, ipamorelin, and MOTS-C. The grouping mixes a growth hormone fragment studied in obesity trials, two growth hormone releasing approaches, and a mitochondrial peptide. No study of the combination was identified. - [Kali](/peptides/stacks/kali): Kali is a named combination of BPC-157, MOTS-C, 5-Amino-1MQ, and tesamorelin. Its components come from tissue signalling, mitochondrial, enzyme inhibition, and growth hormone research respectively. No human study of the combination was identified, and two components have essentially no human evidence at all. - [Kalm](/peptides/stacks/kalm): Kalm is a named combination of semax and selank. Both hold marketing approval in Russia and neither is FDA-approved. No controlled study of the pairing was identified, and neither component is established for cognition or anxiety under U.S. regulatory review. - [Love & Happiness](/peptides/stacks/love-and-happiness): Love & Happiness is a named combination of oxytocin and PT-141. One component has an FDA-approved single-agent product for a specific indication in a specific population. No study of the pairing was identified, and the name describes no outcome. - [Lucid](/peptides/stacks/lucid): Lucid is a named combination of semax, selank, MOTS-C, and tesamorelin. It pairs two Russian-approved neuropeptides with a mitochondrial peptide and a growth hormone releasing analogue. No study of the combination was identified. - [Prometheus](/peptides/stacks/prometheus): Prometheus is a named combination of CJC-1295 and ipamorelin, the most common pairing in the peptide market. Both act on growth hormone release through different receptors. Human evidence for either is limited, and no controlled trial of the pairing itself was identified. - [Samson & Delilah](/peptides/stacks/samson-and-delilah): Samson & Delilah is a named combination of GHK-Cu, CJC-1295, ipamorelin, and TB-500. It mixes copper peptide and tissue repair research with two growth hormone releasing approaches. No study of the combination was identified. - [Selene](/peptides/stacks/selene): Selene is a named combination of GHK-Cu and tesamorelin. One component comes from copper peptide skin research and the other has an FDA-approved product in one narrow indication. No study of the pairing was identified. - [Sentinel](/peptides/stacks/sentinel): Sentinel is a named combination of thymosin alpha-1, BPC-157, KPV, and LL-37. One component has clinical use in some countries outside the United States and the rest are largely preclinical. No study of the combination was identified. - [Valkyr](/peptides/stacks/valkyr): Valkyr is a named combination of BPC-157 and TB-500, the most widely marketed repair pairing in the peptide market. Both are supported almost entirely by animal research. No adequate human trial of either component was identified, and none of the pairing. - [Peptide Education Guides](https://goal.md/peptides/guides): Non-commercial guides on how peptide evidence is read, what human versus animal data supports, and what is not established. - [How GOAL.MD Reviews Peptide Evidence](https://goal.md/peptides/guides/how-goalmd-reviews-peptide-evidence): The process behind the library, stated so it can be held to. - [How Peptide Signaling Works](https://goal.md/peptides/guides/how-peptide-signaling-works): The mechanism layer, explained properly — and the honest limits of what a mechanism can tell you about your own outcome. - [How to Evaluate Peptide Claims](https://goal.md/peptides/guides/evaluating-peptide-claims): Four questions that separate a claim worth investigating from a claim that only sounds specific. - [Human Evidence vs Animal Evidence](https://goal.md/peptides/guides/human-versus-animal-evidence): What a mouse study is designed to answer, what it cannot answer, and how to hold both facts at once. - [Peptide Terminology Glossary](https://goal.md/peptides/guides/peptide-terminology-glossary): The vocabulary used across the library, defined once, with the distinctions that matter. - [Single Peptides vs Named Stacks](https://goal.md/peptides/guides/single-ingredients-versus-stacks): Two different objects, two different evidence questions, and one rule the site never breaks. - [What "Current Availability" Means](https://goal.md/peptides/guides/what-current-availability-means): Not a stock check. A shorthand for several conditions that change independently, and none of which a web page can resolve for you. - [Why Combination Evidence Matters](https://goal.md/peptides/guides/why-combination-evidence-matters): Component data answers a different question. Here is the question it leaves open, and what closing it would require. - [Peptide Match](https://goal.md/calculators/peptide-match): Tell us what you are hoping to improve and see the peptide education most relevant to it, drawn only from GOAL.MD physician-reviewed records.